FindTrial
Sign In

To study early treatment response in peripheral blood on Day 15 in B cell Acute Lymphoblastic Leukemia patients

An observational study to evaluate early treatment response in peripheral blood on Day 15 by flow cytometry in B cell Acute Lymphoblastic Leukemia patients treated with ICiCLe protocol

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2016/08/007180
Enrollment
100
Registered
2016-08-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- B cell Acute Lymphoblastic Leukemia

Interventions

None listed

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: B acute lymphoblastic leukemia patients treated on Indian Childhood Collaborative Leukemia group(ICiCLe)protocol

Exclusion criteria

Exclusion criteria: Patients with following high risk cytogenetics- (i) MLL rearranged leukaemias, e.g. t(4;11) (q21;q23) (ii) Low hypodiploidy ( (iii) t(17;19) (q22;p13) (TCF3-HLF) (iv) Intrachromosomal amplification of chromosome 21 (iAMP21) (v) t(9;22) (q34;q11) (BCR-ABL)

Design outcomes

Primary

MeasureTime frame
Level of MRD by manual analysis and automated analysis on day 15 post induction peripheral blood (%) and categorization into-MRD (Day15 PB) positive/negativeTimepoint: Day 15 post induction—

Secondary

MeasureTime frame
4 year relapse and survival rates for B- ALL patients based on Day 15 and post induction MRD. (This will not be a part of student thesis)Timepoint: 4 years from start of treatment—

Countries

India

Contacts

Public ContactPapagudi Subramanian

Tata Memorial Hospital

worldofketan@rediffmail.com9975864080

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026